1. Home
  2. News
  3. 2019
  4. June

News in June 2019

Browse by year

2019

Browse by month

Get trending consumer news and recalls

    By entering your email, you agree to sign up for consumer news, tips and giveaways from ConsumerAffairs. Unsubscribe at any time.

    Thank you, you have successfully subscribed to our newsletter! Enjoy reading our tips and recommendations.

    Central Aquatics recalls Aqueon Betta Food

    The product may be contaminated with Salmonella

    Central Aquatics of Franklin, Wis., is recalling 96 cases of Aqueon Betta Food.

    The product may be contaminated with Salmonella.

    Fish with Salmonella infections are not well documented and fish carrying salmonella typically do not show any signs of disease.

    No illnesses have been reported to-date.

    The recalled product is sold only in a 0.95-oz plastic jar with the expiration dates of EX04JUN22 and EX05JUN22, item number 100106051, UPC Code 0 15905 06051 6, and manufacturing dates of 06/04/2019 and 06/05, 2019.

    It was shipped to Georgia, Illinois, New Jersey and Pennsylvania via distribution centers.

    What to do

    Customers who purchased the recalled product may return it to the place of purchase for a full refund.

    Consumers with questions may contact Central Aquatics at (888) 255-4527.

    Central Aquatics of Franklin, Wis., is recalling 96 cases of Aqueon Betta Food.The product may be contaminated with Salmonella.Fish with Salmonella...
    Read lessRead more

    Macleods recalls Losartan Potassium and Losartan Potassium/Hydrochlorothiazide tablets

    The products contain trace amounts of a potential human carcinogen

    Macleods Pharmaceuticals Limited is recalling Losartan Potassium tablets and Losartan Potassium/Hydrochlorothiazide combination tablets used to treat hypertension and hypertensive patients with Left Ventricular Hypertrophy.

    The products contain trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA), a potential human carcinogen.

    The firm has not received any reports of adverse events to date.

    The following products, packaged in bottles, are being recalled:

    Losartan Potassium-

    Tablets 50 mg

    NDCManuf.Product DescriptionLotExpiration Date

    33342-

    045-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan

    Potassium.

    Tablets USP

    50mg 90ct

    BLl

    711A

    Nov-19

    33342-

    045-44

    Macleods Pharmac-

    euticals

    Limited

    Losartan

    Potassium

    Tablets USP

    50mg 1000ct

    BLl

    710A

    Nov-19

    Losartan Potassium and Hydro-

    chlorothiazide Tablets 50 mg/ 12.5 mg

    NDCManuf.Product DescriptionLotExpiration Date

    33342-

    050-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan

    Potassium and Hydrochlor-

    othiazide

    Tablets 50 mg/

    12.5 mg

    BLK7

    19A

    Sep-19

    33342-

    050-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan

    Potassium and Hydrochlor-

    othiazide

    Tablets 50

    mg/ 12.5 mg

    BLK7

    20A

    Sep-19

    33342-

    050-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan

    Potassium and Hydrochlor-

    othiazide

    Tablets 50

    mg/ 12.5 mg

    BLK7

    21A

    Sep-19

    33342-

    050-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan

    Potassium

    and Hydrochlor-othiazide Tablets 50 mg/ 12.5 mg

    BLK7

    22A

    Sep-19

    33342-

    050-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan

    Potassium and Hydrochlor-

    othiazide

    Tablets 50

    mg/ 12.5 mg

    BLK7

    23A

    Sep-19

    33342-

    050-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan

    Potassium and Hydrochlor-

    othiazide 

    Tablets 50 

    mg/ 12.5 mg

    BLK7

    24A

    Sep-19

    33342-

    050-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan

    Potassium and Hydrochlor-

    othiazide 

    Tablets 50 

    mg/ 12.5 mg

    BLK7

    25A

    Oct-19

    33342-

    050-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan

    Potassium and Hydrochlor-

    othiazide 

    Tablets 50 

    mg/ 12.5 mg

    BLK72

    6A

    Oct-19

    33342-

    050-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan

    Potassium and Hydrochlor-

    othiazide 

    Tablets 50 

    mg/ 12.5 mg

    BLK8

    04A

    Jan-20

    33342-

    050-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan

    Potassium and Hydrochlor-

    othiazide 

    Tablets 50 

    mg/ 12.5 mg

    BLK8

    06A

    Jan-20

    33342-

    050-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan

    Potassium and Hydrochlor-

    othiazide 

    Tablets 50 

    mg/ 12.5 mg

    BLK8

    25A

    Oct-21

    33342-

    050-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan

    Potassium and Hydrochlor-

    othiazide 

    Tablets 50 

    mg/ 12.5 mg

    BLK8

    26A

    Oct-21

    Losartan Potassium and Hydrochlo.

    Tablets 100 mg/ 12.5 mg

    NDCManuf.Product DescriptionLotExpiration Date

    33342-

    051-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan 

    Potassium 

    and Hydrochlor-

    othiazide 

    Tablets 100

    mg/ 25 mg

    BLL

    801A

    Dec-19

    33342-

    051-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan 

    Potassium 

    and Hydrochlor-

    othiazide 

    Tablets 100

    mg/ 25 mg

    BLL

    802A

    Dec-19

    33342-

    051-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan 

    Potassium 

    and Hydrochlor-

    othiazide 

    Tablets 100

    mg/ 25 mg

    BLL

    803A

    Dec-19

    Losartan Potassium and Hydrochlor.

    Tablets 100 mg/ 25 mg

    NDCManuf.Product DescriptionLotExpiration Date

    33342-

    052-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan

    Potassium

    and Hydrochlor-

    othiazide

    Tablets 100

    mg/ 25 mg

    BLM

    716A

    Jul-19

    33342-

    052-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan 

    Potassium 

    and Hydrochlor-

    othiazide 

    Tablets 100

    mg/ 25 mg

    BLM

    717A

    Jul-19

    33342-

    052-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan 

    Potassium 

    and Hydrochlor-

    othiazide 

    Tablets 100

    mg/ 25 mg

    BLM

    719A

    Aug-19

    33342-

    052-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan 

    Potassium 

    and Hydrochlor-

    othiazide 

    Tablets 100

    mg/ 25 mg

    BLM

    720A

    Aug-19

    33342-

    052-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan 

    Potassium 

    and Hydrochlor-

    othiazide 

    Tablets 100

    mg/ 25 mg

    BLM

    721A

    Sep-19

    33342-

    052-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan 

    Potassium 

    and Hydrochlor-

    othiazide 

    Tablets 100

    mg/ 25 mg

    BLM

    722A

    Sep-19

    33342-

    052-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan 

    Potassium 

    and Hydrochlor-

    othiazide 

    Tablets 100

    mg/ 25 mg

    BLM

    723A

    Oct-19

    33342-

    052-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan 

    Potassium 

    and Hydrochlor-

    othiazide 

    Tablets 100

    mg/ 25 mg

    BLM

    724A

    Oct-19

    33342-

    052-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan 

    Potassium 

    and Hydrochlor-

    othiazide 

    Tablets 100

    mg/ 25 mg

    BLM

    725A

    Oct-19

    33342-

    052-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan 

    Potassium 

    and Hydrochlor-

    othiazide 

    Tablets 100

    mg/ 25 mg

    BLM

    726A

    Nov-19

    33342-

    052-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan 

    Potassium 

    and Hydrochlor-

    othiazide 

    Tablets 100

    mg/ 25 mg

    BLM

    802A

    Dec-19

    33342-

    052-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan 

    Potassium 

    and Hydrochlor-

    othiazide 

    Tablets 100

    mg/ 25 mg

    BLM

    803A

    Dec-19

    33342-

    052-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan 

    Potassium 

    and Hydrochlor-

    othiazide 

    Tablets 100

    mg/ 25 mg

    BLM

    825A

    Sep-21

    33342-

    052-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan 

    Potassium 

    and Hydrochlor-

    othiazide 

    Tablets 100

    mg/ 25 mg

    BLM

    826A

    Sep-21

    33342-

    052-10

    Macleods Pharmac-

    euticals

    Limited

    Losartan 

    Potassium 

    and Hydrochlor-

    othiazide 

    Tablets 100

    mg/ 25 mg

    BLM

    827A

    Sep-21

    The products can be identified by checking the product name, manufacturer details and batch or lot number on the bottle.

    What to do

    Patients who are on the recalled medications should continue taking them and contact their pharmacist, physician, or medical provider for advice regarding an alternative treatment, as the risk of harm to the patient's health may be higher if the treatment is stopped immediately without any alternative treatment.

    Patients with medical questions regarding this recall or to report an adverse event may contact Macleods at (855) 926-3384 (8:00 am – 5:00 pm (EST).

    Macleods is arranging for return of all recalled products to Qualanex. Instructions for returning recalled products are given in the recall letter.

    Consumers with general questions regarding the return of the recalled product may contact Qualanex (888) 280-2046, 7:00 am to 4:00 pm (CST) Monday – Friday or by email at recall@qualanex .com.

    Macleods Pharmaceuticals Limited is recalling Losartan Potassium tablets and Losartan Potassium/Hydrochlorothiazide combination tablets used to treat hyper...
    Read lessRead more

    Get trending consumer news and recalls

      By entering your email, you agree to sign up for consumer news, tips and giveaways from ConsumerAffairs. Unsubscribe at any time.

      Thank you, you have successfully subscribed to our newsletter! Enjoy reading our tips and recommendations.

      San Francisco makes its ban on e-cigarettes official

      Teen use continues to be at the top of government and health officials’ list of concerns

      On Tuesday, San Francisco became the first U.S. city to ban e-cigarettes when city officials passed an ordinance prohibits selling nicotine “pods” -- cartridges that contain nicotine and used in a vaporizer -- or electronic smoking devices that haven’t been approved by the Food and Drug Administration (FDA).

      “There is so much we don’t know about the health impacts of these products, but we do know that e-cigarette companies are targeting our kids in their advertising and getting them hooked on addictive nicotine products,” San Francisco mayor London Breed said in a statement.

      Who’ll be the next to step up?

      It’ll be interesting to see if San Francisco’s ban catches fire and moves to other cities. Two other cities in the Bay Area --  the cities of Richmond and Livermore -- have already announced that they may follow in San Francisco’s footsteps.

      On a state level, 48 states have laws in place prohibiting access to e-cigarettes for people up to 18 years old or older. 

      On the federal level, the initiative has great support from the FDA. Last year, the agency carried out the largest coordinated enforcement effort in the FDA’s history when it issued more than 1,300 warning letters and fines to businesses that illegally sold e-cigarette products to minors.

      Manufacturers say they’re on board, at least with teen use

      Teens are the primary consumer target for e-cig companies. Close to 21 percent of U.S. high school students and 5 percent of middle schoolers say they’ve used electronic cigarettes in the past 30 days. Adding to that concern is an estimate that some addicted minors spend as much as $1,500 per year feeding their e-cig habit.

      Juul -- the largest e-cig manufacturer, one owned in part by Altria, the parent company of Philip Morris -- has its white hat on and says it’s behind the prohibition to minors all the way. In its “commitment to youth prevention,” Juul promises it will:

      • Suspend the distribution of non-tobacco and non-menthol-based flavored JUUL products to retail outlets;

      • Enhance its e-commerce platform to ensure purchasers are 21+ and to prevent bulk purchases;

      • Promote retailer compliance to ensure retail stores do not sell JUUL products to those underage;

      • Exit its U.S. Facebook and Instagram accounts; and

      • Develop technology-based solutions to prevent youth use.

      Finding out the full impact will take time

      It’s too early to predict the long-term effects of e-cigarette smoking. With tobacco, there were decades of use and diseases to draw from. But researchers are already seeing some similarity in how genes and proteins are affected. 

      “While many of the chemicals found in e-liquids are FDA approved, they are approved for ingestion, not inhalation,” said UNC School of Medicine toxicologist Ilona Jaspers. “When you switch the route of exposure (inhaling instead on ingesting), and go through the lung, the lung is really not a good organ to metabolize foreign compounds.”

      On Tuesday, San Francisco became the first U.S. city to ban e-cigarettes when city officials passed an ordinance prohibits selling nicotine “pods” -- cartr...
      Read lessRead more

      FTC and states launch coordinated action against robocallers

      Law enforcement tries to stem the rising tide of illegal and annoying phone calls

      The Federal Trade Commission (FTC) and a number of states have joined forces to crack down on illegal robocalls. 

      The law enforcement partners announced a total of 94 actions targeting telemarketers around the country that are responsible for at least some of the calls -- interruptions that pitch everything from bogus interest rate reduction services to money-making schemes to medical alert systems.

      “We’re all fed up with the tens of billions of illegal robocalls we get every year,” said Andrew Smith, director of the FTC’s Bureau of Consumer Protection. “Today’s joint effort shows that combating this scourge remains a top priority for law enforcement agencies around the nation.”

      Florida seeks injunction

      In Florida, Attorney General Ashley Moody filed a Stipulated Order for Permanent Injunction and Monetary Judgment against Lifewatch, Inc., and MedGuard Alert, Inc., marketers of health monitors.

      “I am committed to protecting the rights of Illinois consumers, and that includes defending against illegal robocalls,” said Illinois Attorney General Kwame Raoul. “Robocalls cost consumers time and money and violate their privacy. I am proud to be part of this joint effort to take further action to stop this illegal and intrusive practice.” 

      Raoul’s office filed a lawsuit against Glamour Services Awe Struck, two companies the attorney general said have been using robocalling and telemarketing to sell home cleaning services. The suit claims many consumers receiving calls from these companies are registered on the Do Not Call List.

      The joint crackdown, called “Operation Call it Quits,” is part of the FTC’s ongoing campaign to help stem the tide of universally hated pre-recorded telemarketing calls. In addition, the agency said it is promoting development of technology-based solutions to block robocalls and combat caller ID spoofing.

      Michigan settles with natural gas company

      As part of the campaign, Michigan Attorney General Dana Nessel announced a settlement with Ardent Natural Gas in March, resolving alleged violations of the Home Solicitation Sales Act for using robocalls to illegally solicit Michigan consumers. 

      As part of her contribution to the effort, Nessel’s office has already hosted 125 consumer education seminars warning consumers about the dangers of robocalls and e-scams.

      “It’s time to put a stop to this public nuisance,” Nessel said. “This is only the beginning of several efforts by the Michigan Attorney General’s Office to combat this epidemic perpetuated by negligent companies who see nothing more than dollar signs at the other end of the phone line.”

      The FTC also announced several cases that are pending against alleged robocallers. The agency is taking action against companies pitching credit card reduction plans and fraudulent money-making schemes.

      The Federal Trade Commission (FTC) and a number of states have joined forces to crack down on illegal robocalls. The law enforcement partners announced...
      Read lessRead more

      Firefox launches project designed to trick advertisers

      Track THIS gives users four ‘alter ego’ choices to confuse ad-trackers

      Mozilla recently launched Track THIS, a browsing history project that can help consumers dupe advertisers through the creation of depersonalized browser behavior. 

      Track THIS, the result of a collaboration between Mschf Internet Studios and Mozilla’s Firefox, “opens up 100 tabs crafted to fit a specific character—a hypebeast, a filthy rich person, a doomsday prepper, or an influencer,” explains Vice

      Touted as “a new kind of incognito” browsing project, Track THIS was created with the aim of showing internet users how third-party ad trackers work. 

      “These trackers and these websites really commoditize you, and they don’t really make you feel like a person,” Daniel Greenberg, director of strategy and distribution for mschf, told Vice. “So we wanted to do something visceral that makes the user feel like they’re in control again.”

      Four ‘alter ego’ choices

      Users can choose from one of four “alter egos” -- Hypebeast, Filthy Rich, Doomsday, or Influencer -- and Track THIS will “open 100 tabs of pure madness to fool trackers into thinking you're someone else.” 

      “This will show you ads for products you might not be interested in at all, so it’s really just throwing off brands who want to advertise to a very specific type of person,” Mozilla said in a press release. “You’ll still be seeing ads. And eventually, if you just use the internet as you typically would day to day, you’ll start seeing ads again that align more closely to your normal browsing habits.” 

      The project is part of a push by Firefox to show users how they’re being tracked. Ultimately, Firefox is aiming to get users on board with its Enhanced Tracking Protection feature, which offers stronger privacy protection. 

      “If you’d rather straight-up block third-party tracking cookies, go ahead and get Enhanced Tracking Protection in Firefox,” the company said. 

      Mozilla recently launched Track THIS, a browsing history project that can help consumers dupe advertisers through the creation of depersonalized browser be...
      Read lessRead more

      FDA warns kratom makers to stop marketing products with unproven claims

      Two companies have been told to stop touting kratom-containing products as treatments or cures for opioid addiction

      The Food and Drug Administration (FDA) has issued warnings to two kratom marketers that have been accused of illegally selling products with “unproven” claims about the herbal extract’s ability to treat or cure opioid addiction and withdrawal. 

      The warning letters were sent to Cali Botanicals of Folsom, Calif., and Kratom NC of Wilmington, N.C. and are part of a larger effort being made by the FDA to inform consumers of the dangers associated with the use of kratom. 

      The agency said it has already issued many warnings about the risks associated with kratom, but companies are still selling the product and making “deceptive medical claims that are not backed by science or any reliable scientific evidence.” 

      Numerous warnings

      Within the past year, the FDA has found high levels of heavy metals in kratom products and linked kratom products to a multistate salmonella outbreak. Adverse health effects of using kratom -- which isn’t approved by the FDA -- can include dizziness, drowsiness, breathing suppression, coma, and death. 

      “We have issued numerous warnings about the serious risks associated with the use of kratom, including warnings about the contamination of kratom products with high rates of salmonella that put people using kratom products at risk, and resulted in numerous illnesses and recalls,” acting FDA Commissioner Ned Sharpless said in a statement.

      Last February, then-commissioner Scott Gottlieb said that not only is there no evidence to indicate that kratom is safe or effective for any medical use, but the scientific data and adverse event reports have “clearly revealed” that compounds in kratom render it more dangerous than “just a plant.” 

      Could delay proper care

      The FDA is concerned that companies marketing kratom as a potential treatment for opioid abuse could prevent those who are addicted to opioids from seeking proper care. 

      “Using products with unsubstantiated claims may prevent those addicted to opioids from seeking treatments that have been demonstrated to be safe and effective,” the agency said. “Reliance on products with unsubstantiated claims may delay their path to recovery and put them at greater risk of addiction, overdose and death.” 

      The FDA has given the companies 15 working days to submit their plan to correct their violations.

      “As we work to combat the opioid crisis, we cannot allow unscrupulous vendors to take advantage of consumers by selling products with unsubstantiated claims that they can treat opioid addiction or alleviate other medical conditions,” Sharpless said. 

      The Food and Drug Administration (FDA) has issued warnings to two kratom marketers that have been accused of illegally selling products with “unproven” cla...
      Read lessRead more

      Gold prices rise to the highest level in six years

      A weaker dollar and rising global tensions are partly responsible

      Chances are you’re starting to see commercials for gold on cable TV again. That’s because the precious metal has been gaining value in recent weeks, hitting a six-year high on Tuesday.

      What’s behind the move? Part of it resides in the Federal Reserve. Conventional wisdom holds that the Fed is about to embark on an interest rate-cutting cycle, with perhaps one or two rate cuts before the end of the year.

      That belief has sent the dollar lower, and since gold is priced in dollars, it now takes more dollars to buy an ounce of gold than it did a few weeks ago. But geopolitical events may also be playing a role.

      Money tends to pour into gold during times of international tension and political uncertainty. Gold moved sharply higher as incidents in the Persian Gulf brought U.S. and Iranian military forces nose to nose. After Iran shot down an unmanned U.S. drone, President Trump was reportedly close to launching a military strike in retaliation.

      Spot gold rose nearly 1 percent Tuesday to $1,432.42 per ounce, the highest it’s been since May 2013. U.S. gold futures were slightly higher than that.

      Several options

      For investors seeking to put a few dollars into the precious metal, there are several options. But it’s worth noting that expert opinions differ on where gold goes from here. George Gero, managing director at RBC Wealth Management, tells Reuters that uptrends like the one gold is in don’t end overnight. He sees gold moving still higher in the short run.

      But writing on the Kitco Metals website, analyst Jim Wyckoff describes the gold trade as “overbought and due for a normal and healthy downside correction very soon.”

      The commercials on TV for gold are promoting “physical” gold -- things like gold coins and bars. While many investors like the idea of having gold on hand, storing it securely can sometimes be an issue.

      Where to buy

      It is also important to purchase gold from a reputable dealer. ConsumerAffairs has reviews of nearly a dozen gold dealers here.

      Investors can also own gold without taking physical possession of it. Shares of SPDR Gold Shares is an ETF backed by physical gold. Shares are traded on the New York Stock Exchange (NYSE) and can be bought and sold through an online trading platform. The share price is up about 24 percent over the last 12 months.

      As with any financial investment, it is always a good idea to seek the advice of a trusted and objective financial advisor before committing funds.

      Chances are you’re starting to see commercials for gold on cable TV again. That’s because the precious metal has been gaining value in recent weeks, hittin...
      Read lessRead more

      San Giuseppe Salami Co. by Giacomo recalls andouille sausage

      The product may may be contaminated with extraneous materials

      San Giuseppe Salami Co. by Giacomo of Elon, N.C., is recalling approximately 832 pounds of ready-to-eat, frozen andouille sausage.

      The product may may be contaminated with extraneous materials -- specifically metal.

      There are no confirmed reports of adverse reactions.

      The following item, produced on May 14, 2019, is being recalled:

      • Varying weights of vacuum-packed, individually-sealed packages containing “SAN GIUSEPPE SALAMI CO. BY GIACOMO ANDOUILLE SAUSAGE (SMOKE FLAVORING ADDED)” with a “Sell By: 11/10/2019” date on the case labels.

      The recalled product, bearing establishment number “EST. 21556” inside the USDA mark of inspection, was shipped to retail and institutional locations in Greensboro, N.C.

      What to do

      Customers who purchased the recalled product should not consume it, but discard or return it to the place of purchase.

      Consumers with questions may contact Francisco Grijalva or Giacomo Santomauro at (336) 586-7003, or by email at Francesco@sgsalami.com and Giacomo@sgsalami.com, respectively.

      San Giuseppe Salami Co. by Giacomo of Elon, N.C., is recalling approximately 832 pounds of ready-to-eat, frozen andouille sausage.The product may may b...
      Read lessRead more

      Bernie Sanders proposes plan to cancel $1.6 trillion in student debt

      ‘It’s time to hit the reset button,' says the Vermont senator

      Democratic presidential candidate Bernie Sanders has unveiled a plan to eliminate all student loans through a new tax on Wall Street transactions. The plan would also make two- and four-year public colleges and universities free to attend.

      “The bottom line is we shouldn’t be punishing people for getting to higher education,” Sanders said at a news conference in Washington on Monday. “It is time to hit the reset button. Under the proposal that we introduced today, all student debt would be canceled in six months.”

      "We will make a full and complete education a human right," Sanders said. 

      In April, Senator and presidential hopeful Elizabeth Warren (D-Mass.) announced a proposal that would wipe out $50,000 in debt for each person with a household income of less than $100,000. Sanders’ plan goes a step further by taking income eligibility out of the equation. 

      "This proposal completely eliminates student debt in this country and ends the absurdity of sentencing an entire generation, the millennial generation, to a lifetime of debt for the crime of doing the right thing - and that is going out and getting a higher education,” Sanders said. 

      Taxing Wall Street

      The plan would include a 0.5 percent tax on stock transactions and a 0.1 percent tax on bonds, which would generate an estimated $2.4 trillion over the next ten years. 

      Sanders’ campaign says the proposal would erase $1.6 trillion in outstanding student loan debt carried by 45 million Americans. A majority of the initiative’s benefits (73 percent) would go to Americans with incomes of less than $127,000 per year. 

      "During the financial crisis, Wall Street received the largest taxpayer bailout in American history. Now it is Wall Street's turn to help rebuild the middle class. #CancelStudentDebt," Sanders tweeted Monday. 

      Democratic presidential candidate Bernie Sanders has unveiled a plan to eliminate all student loans through a new tax on Wall Street transactions. The plan...
      Read lessRead more

      Study shows average senior has saved $200,000 for retirement

      But Vanguard researchers say many have saved much less

      Americans have been told they need to save for retirement for decades, but a new survey on the subject from Vanguard shows that not everyone has been listening.

      The survey-takers talked with people nearing retirement age about their saving and spending habits and about how much they had socked away in retirement accounts. For those who had 401(k) accounts, the average balance was a little less than $200,000.

      But the situation might be even worse. The median amount of savings for adults who are at least 65 is just $58,000. That means most people in the survey had saved considerably less than the average.

      Concerns remain the same

      The Vanguard researchers say retirement plans have improved since 2006, when Congress passed broader incentives to encourage retirement plan participation. They note that plan participation has, in fact, improved since then.

      “However, as we look to the future, the main concerns affecting retirement savings plans largely remain the same -- improving plan participation and contribution rates even further and continuing to enhance portfolio diversification, enabling more individuals to retire with sufficient assets,” the researchers wrote.

      The report traced the poor performance to three main factors -- income, age, and how long an individual had been at a particular job. It also found gender played a role.

      “Sixty percent of Vanguard participants are male, and men have average and median balances that are about 50 percent higher than those of women,” the report said. “Gender is often a proxy for other factors, such as income and job tenure.”

      Of participants taking part in the survey, men had an average of nearly $107,000 tucked away while women, on average, had $72,451. The researchers found women earned less than men and hadn’t been at their jobs as long as men.

      But when all things were equal -- with women earning the same and having the same job tenure -- they tended to save more than their male counterparts.

      Other studies

      Other studies have shown people nearing retirement have less-than-adequate savings. A 2015 study by the General Accountability Office (GAO) found that half of older Americans had no money saved for retirement. When asked why, many said they had no money left over after paying expenses.

      Perhaps because of that, a 2018 survey by Careerbuilder showed more than half of workers aged 60 years or older said they are postponing retirement plans. Worries about having enough money to last through retirement appeared to be the overriding reason.

      The survey showed 53 percent of age 60-plus workers are putting off retirement, with significantly more men making that decision than women. Four out of 10 workers said they don't think they can retire until at least age 70.

      Americans have been told they need to save for retirement for decades, but a new survey on the subject from Vanguard shows that not everyone has been liste...
      Read lessRead more